FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000814575> ?p ?o ?g. }

• W2000814575 endingPage "958.e1" @default.
• W2000814575 startingPage "951" @default.
• W2000814575 abstract "Purpose Ocular Tracking Resistance in U.S. Today (TRUST) annually evaluates in vitro antimicrobial susceptibility of Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, penicillin, azithromycin, tobramycin, trimethoprim, and polymyxin B in national samples of ocular isolates. Design Laboratory investigation. Methods Prospectively collected ocular isolates (197 S. aureus, 49 S. pneumoniae, and 32 H. influenzae) from 35 institutions and archived ocular isolates (760 S. pneumoniae and 356 H. influenzae) from 34 institutions were tested by an independent, central laboratory. Mean minimum inhibitory concentrations that would inhibit growth of 90% of the tested isolates (MIC90) were interpreted as susceptible, intermediate, or resistant according to standardized breakpoints for systemic treatment. S. aureus isolates were classified as methicillin susceptible (MSSA) or methicillin resistant (MRSA). Results MSSA or MRSA susceptibility patterns were virtually identical for the fluoroquinolones, that is, MSSA susceptibility was 79.9% to 81.1% and MRSA susceptibility was 15.2%. Trimethoprim was the only agent tested with high activity against MRSA. All S. pneumoniae isolates were susceptible to gatifloxacin, levofloxacin, and moxifloxacin; 89.8% were susceptible to ciprofloxacin. H. influenzae isolates were 100% susceptible to all tested agents but trimethoprim. Ocular TRUST 1 data were consistent with the eight-year longitudinal sample of archived ocular isolates. Conclusions The fluoroquinolones were consistently active in MSSA, S. pneumoniae, and H. influenzae. After more than a decade of intensive ciprofloxacin and levofloxacin use as systemic therapy, 100% of ocular S. pneumoniae isolates were susceptible to gatifloxacin, levofloxacin, and moxifloxacin; nonsusceptibility to ciprofloxacin was less than 15%. High-level in vitro MRSA resistance suggests the need to consider alternative therapy to fluoroquinolones when MRSA is a likely pathogen. Ocular Tracking Resistance in U.S. Today (TRUST) annually evaluates in vitro antimicrobial susceptibility of Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, penicillin, azithromycin, tobramycin, trimethoprim, and polymyxin B in national samples of ocular isolates. Laboratory investigation. Prospectively collected ocular isolates (197 S. aureus, 49 S. pneumoniae, and 32 H. influenzae) from 35 institutions and archived ocular isolates (760 S. pneumoniae and 356 H. influenzae) from 34 institutions were tested by an independent, central laboratory. Mean minimum inhibitory concentrations that would inhibit growth of 90% of the tested isolates (MIC90) were interpreted as susceptible, intermediate, or resistant according to standardized breakpoints for systemic treatment. S. aureus isolates were classified as methicillin susceptible (MSSA) or methicillin resistant (MRSA). MSSA or MRSA susceptibility patterns were virtually identical for the fluoroquinolones, that is, MSSA susceptibility was 79.9% to 81.1% and MRSA susceptibility was 15.2%. Trimethoprim was the only agent tested with high activity against MRSA. All S. pneumoniae isolates were susceptible to gatifloxacin, levofloxacin, and moxifloxacin; 89.8% were susceptible to ciprofloxacin. H. influenzae isolates were 100% susceptible to all tested agents but trimethoprim. Ocular TRUST 1 data were consistent with the eight-year longitudinal sample of archived ocular isolates. The fluoroquinolones were consistently active in MSSA, S. pneumoniae, and H. influenzae. After more than a decade of intensive ciprofloxacin and levofloxacin use as systemic therapy, 100% of ocular S. pneumoniae isolates were susceptible to gatifloxacin, levofloxacin, and moxifloxacin; nonsusceptibility to ciprofloxacin was less than 15%. High-level in vitro MRSA resistance suggests the need to consider alternative therapy to fluoroquinolones when MRSA is a likely pathogen." @default.
• W2000814575 created "2016-06-24" @default.
• W2000814575 creator A5003459349 @default.
• W2000814575 creator A5006245542 @default.
• W2000814575 creator A5010693183 @default.
• W2000814575 creator A5026160198 @default.
• W2000814575 creator A5038009031 @default.
• W2000814575 creator A5059316189 @default.
• W2000814575 creator A5062658387 @default.
• W2000814575 creator A5078689711 @default.
• W2000814575 date "2008-06-01" @default.
• W2000814575 modified "2023-10-10" @default.
• W2000814575 title "Ocular TRUST: Nationwide Antimicrobial Susceptibility Patterns in Ocular Isolates" @default.
• W2000814575 cites W1589822958 @default.
• W2000814575 cites W1866015860 @default.
• W2000814575 cites W1867869915 @default.
• W2000814575 cites W1972288217 @default.
• W2000814575 cites W1972326820 @default.
• W2000814575 cites W2009639913 @default.
• W2000814575 cites W2031888076 @default.
• W2000814575 cites W2037823432 @default.
• W2000814575 cites W2040443954 @default.
• W2000814575 cites W2047055639 @default.
• W2000814575 cites W2050908776 @default.
• W2000814575 cites W2069458838 @default.
• W2000814575 cites W2095785718 @default.
• W2000814575 cites W2100498945 @default.
• W2000814575 cites W2102310843 @default.
• W2000814575 cites W2106414496 @default.
• W2000814575 cites W2107188035 @default.
• W2000814575 cites W2107372728 @default.
• W2000814575 cites W2109203736 @default.
• W2000814575 cites W2114535764 @default.
• W2000814575 cites W2121949549 @default.
• W2000814575 cites W2122273366 @default.
• W2000814575 cites W2132279294 @default.
• W2000814575 cites W2147921400 @default.
• W2000814575 cites W2161981311 @default.
• W2000814575 cites W2169920555 @default.
• W2000814575 doi "https://doi.org/10.1016/j.ajo.2008.01.025" @default.
• W2000814575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18374299" @default.
• W2000814575 hasPublicationYear "2008" @default.
• W2000814575 type Work @default.
• W2000814575 sameAs 2000814575 @default.
• W2000814575 citedByCount "199" @default.
• W2000814575 countsByYear W20008145752012 @default.
• W2000814575 countsByYear W20008145752013 @default.
• W2000814575 countsByYear W20008145752014 @default.
• W2000814575 countsByYear W20008145752015 @default.
• W2000814575 countsByYear W20008145752016 @default.
• W2000814575 countsByYear W20008145752017 @default.
• W2000814575 countsByYear W20008145752018 @default.
• W2000814575 countsByYear W20008145752019 @default.
• W2000814575 countsByYear W20008145752020 @default.
• W2000814575 countsByYear W20008145752021 @default.
• W2000814575 countsByYear W20008145752022 @default.
• W2000814575 countsByYear W20008145752023 @default.
• W2000814575 crossrefType "journal-article" @default.
• W2000814575 hasAuthorship W2000814575A5003459349 @default.
• W2000814575 hasAuthorship W2000814575A5006245542 @default.
• W2000814575 hasAuthorship W2000814575A5010693183 @default.
• W2000814575 hasAuthorship W2000814575A5026160198 @default.
• W2000814575 hasAuthorship W2000814575A5038009031 @default.
• W2000814575 hasAuthorship W2000814575A5059316189 @default.
• W2000814575 hasAuthorship W2000814575A5062658387 @default.
• W2000814575 hasAuthorship W2000814575A5078689711 @default.
• W2000814575 hasConcept C2776925733 @default.
• W2000814575 hasConcept C2777653605 @default.
• W2000814575 hasConcept C2778512257 @default.
• W2000814575 hasConcept C2778836808 @default.
• W2000814575 hasConcept C2779489039 @default.
• W2000814575 hasConcept C2780728791 @default.
• W2000814575 hasConcept C2781253189 @default.
• W2000814575 hasConcept C2781276175 @default.
• W2000814575 hasConcept C4937899 @default.
• W2000814575 hasConcept C501593827 @default.
• W2000814575 hasConcept C523546767 @default.
• W2000814575 hasConcept C54355233 @default.
• W2000814575 hasConcept C71924100 @default.
• W2000814575 hasConcept C86803240 @default.
• W2000814575 hasConcept C89423630 @default.
• W2000814575 hasConceptScore W2000814575C2776925733 @default.
• W2000814575 hasConceptScore W2000814575C2777653605 @default.
• W2000814575 hasConceptScore W2000814575C2778512257 @default.
• W2000814575 hasConceptScore W2000814575C2778836808 @default.
• W2000814575 hasConceptScore W2000814575C2779489039 @default.
• W2000814575 hasConceptScore W2000814575C2780728791 @default.
• W2000814575 hasConceptScore W2000814575C2781253189 @default.
• W2000814575 hasConceptScore W2000814575C2781276175 @default.
• W2000814575 hasConceptScore W2000814575C4937899 @default.
• W2000814575 hasConceptScore W2000814575C501593827 @default.
• W2000814575 hasConceptScore W2000814575C523546767 @default.
• W2000814575 hasConceptScore W2000814575C54355233 @default.
• W2000814575 hasConceptScore W2000814575C71924100 @default.
• W2000814575 hasConceptScore W2000814575C86803240 @default.
• W2000814575 hasConceptScore W2000814575C89423630 @default.
• W2000814575 hasIssue "6" @default.
• W2000814575 hasLocation W20008145751 @default.

• next